Ran Nina A, Payne Aimee S
Department of Dermatology, University of Pennsylvania, 1009 Biomedical Research Building, 421 Curie Boulevard, PA, USA.
F1000Res. 2017 Jan 27;6:83. doi: 10.12688/f1000research.9476.1. eCollection 2017.
Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has been FDA-approved for rheumatoid arthritis and vasculitides, such as granulomatosis with polyangiitis and microscopic polyangiitis. Additionally, rituximab has been used off-label in the treatment of numerous other autoimmune diseases, with notable success in pemphigus, an autoantibody-mediated skin blistering disease. The efficacy of rituximab therapy in pemphigus has spurred interest in its potential to treat other autoantibody-mediated diseases. This review summarizes the efficacy of rituximab in pemphigus and examines its off-label use in other select autoantibody-mediated diseases.
利妥昔单抗是一种靶向B细胞标志物CD20的单克隆抗体，1997年最初被美国食品药品监督管理局（FDA）批准用于治疗非霍奇金淋巴瘤。从那时起，利妥昔单抗已获得FDA批准用于治疗类风湿性关节炎和血管炎，如肉芽肿性多血管炎和显微镜下多血管炎。此外，利妥昔单抗还被用于许多其他自身免疫性疾病的非标签治疗，在天疱疮（一种自身抗体介导的皮肤水疱病）的治疗中取得了显著成功。利妥昔单抗治疗天疱疮的疗效激发了人们对其治疗其他自身抗体介导疾病潜力的兴趣。本综述总结了利妥昔单抗在天疱疮中的疗效，并探讨了其在其他特定自身抗体介导疾病中的非标签使用情况。
